Home Biosimilar Antibodies Immunology & Inflammation CD markers Brentuximab (Anti-TNFRSF8 / CD30)
For research use only. Not for use in humans.

Brentuximab (Anti-TNFRSF8 / CD30)

Brentuximab (Anti-TNFRSF8 / CD30) is a chimeric monoclonal antibody targeting anti-CD30 with antineoplastic activity. It has the potential to alter the disease course of non-MF/SS CTCLs. MW : 145.38 KD.

Brentuximab (Anti-TNFRSF8 / CD30)

1 Citation

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A232201 Purity: 99% Protein concentration: 4.46mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Brentuximab (Anti-TNFRSF8 / CD30) is a chimeric monoclonal antibody targeting anti-CD30 with antineoplastic activity. It has the potential to alter the disease course of non-MF/SS CTCLs. MW : 145.38 KD.

Product Details

CAS No. 2088770-90-3
Molecular Weight 145.38 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06617286 NOT_YET_RECRUITING Classical Hodgkin Lymphoma New York Medical College 2026-12-01 PHASE1; PHASE2
NCT07178457 NOT_YET_RECRUITING Drug: Brentuximab Vedotin (Bv)|Drug: Placebo Cutaneous T Cell Lymphoma (CTCL); Brentuximab Vedotin Assistance Publique - Hôpitaux de Paris 2025-11-01 PHASE3
NCT07575893 NOT_YET_RECRUITING Drug: Bendamustin|Drug: Fludarabine Classical Hodgkin Lymphoma New York Medical College 2026-10-01 PHASE1
NCT05675410 RECRUITING Drug: Brentuximab Vedotin|Drug: Cyclophosphamide|Drug: Dacar Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 National Cancer Institute (NCI) 2023-05-11 PHASE3
NCT04685616 RECRUITING Drug: Doxorubicin|Drug: Bleomycin|Drug: Brentuximab vedotin| Hodgkin Lymphoma University College, London 2022-04-14 PHASE3
NCT07002216 RECRUITING Drug: Brentuximab Vedotin|Drug: Etoposide|Drug: Cyclophospha Hodgkin Lymphoma; Advanced Hodgkin Lymphoma University of Miami 2025-07-15 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-04-15)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.